A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-? Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn`s Disease
The purpose of the HARMONY study is to assess the safety and efficacy of an investigational
drug called HuZAF, in patients with moderate to severe Crohn`s disease (CD). HuZAF is a
humanized anti-Interferon-gamma (anti-IFN-?) monoclonal antibody, which binds and blocks
IFN-?, a protein in the immune system that is involved in inflammation. Antibodies are
proteins normally produced by our immune system to help fight off foreign substances.
Scientists have been able to make therapeutic humanized monoclonal antibodies, similar to
the antibodies in our bodies, to target diseases.
Study Status: Completed
Digestive System Disease
Drug: anti-Interferon-gamma monoclonal antibody
Information provided by:
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
The Cleveland Clinic Foundation
Cleveland, Ohio 44195